EADV CONGRESS 2022
Hair Sessions Highlights by Dr. Sergio Vañó Galván

Dermatologist and trichologist
Head of the Trichology Unit at Ramón y Cajal Hospital, Madrid, Spain

  • 6min (reading time)
  • Supported by
    • Dercos

DERCOS ACADEMY REPORT
Dr. Sergio Vañó-Galván
European Academy of Dermatology Congress 2022 (Milano)


SUMMARY

Between other interesting topics, I would highlight the following data from the last face to face EADV congress that was held in Milano (sept. 2022):


1. JAK INHIBITORS FOR ALOPECIA AREATA: the recent FDA and EMA approval of baricitinib for severe alopecia areata (AA) has started a new era in the treatment of alopecia areata. JAK inhibitors have demonstrated to be effective for AA with a favourable safety profile. The new JAKi (JAKi) includes baricitinib (JAK1 and JAK2 inhibitor), deuruxolitinib (JAK1 and JAK2 inhibitor) and ritlecinitib (JAK3 inhibitor). More than 40% of severe AA patients (more than 50% of scalp affected) treated with these drugs achieve an improvement of 80% of regrowth or more. The most frequent side effects include upper respiratory tract infections, acne, headache and nasopharyngitis.


Practical management of JAK inhibitors for alopecia areata
Figure 1. Practical management of JAK inhibitors for alopecia areata (Dr. Sergio Vañó)


2. OTHER NEW THERAPIES FOR ALOPECIA AREATA: Dr. Vañó, Dr. Piraccini and Dr. Blume-Peytavi showed new options for patients with AA. Oral etrasimod (sphingosine 1 phosphate receptor modulator), dupilumab (IL4 and IL 13 inhibitor), topical LHH8 (coacillium 21%) and the combination of topical imiquimod 5% and topical dyphencyprone were discussed.


3. NEW TREATMENTS FOR ANDROGENETIC ALOPECIA: Dr. Shapiro discussed new therapies for androgenetic alopecia, including platelet rich plasma, exosomes, self-assembled micelle inhibitory RNA and stem cell technologies. I would highlight exosomes, which are extracellular vesicles containing peptides, growth factors, RNA and lipids that may stimulate hair growth. They are secreted from cells for communication. There are premade kits with allogenic exosomes ready for injection, although they are not FDA or EMA approved. FDA has cautioned patients on these products as unapproved regenerative therapies. Therefore, further research needs to be done before its application in clinical practice.